key: cord-0985759-cbwvnmuj authors: Bakhsh, Abeer; AlQaseer, Maryam; AlAyoubi, Fakhr; Bader, Rima S.; Alghalayini, Kamal; ElAsfar, Abdelfatah; Alhabeeb, Waleed title: Health Care Delivery for Heart Failure Patients During The COVID-19 Pandemic; A Consensus of The Saudi Heart Failure Working Group (SAUDI-HF) date: 2020-06-22 journal: J Saudi Heart Assoc DOI: 10.37616/2212-5043.1073 sha: 8620ca0f3850e5a875d325bdde92fc91513cdec4 doc_id: 985759 cord_uid: cbwvnmuj The Coronavirus disease 2019 (COVID-19) pandemic led to global and national rapid health system changes to treat the affected patients and prevent the spread of the virus. The social distancing, redirecting resources, and nationwide lockdown led to the cancellation of non-urgent hospital visits and interruption of continuity of care for patients with chronic cardiac conditions such as heart failure (HF). This consensus document addresses the domains of health care delivery that are affected by the pandemic. It explains the current situation of health care delivery to heart failure patients and further recommendation on how to overcome this. Thus, maintaining quality and continuity of care to the HF population. Health Care Delivery for Heart Failure Patients During The COVID-19 Pandemic; A Consensus of The Saudi Heart Failure Working Group (SAUDI-HF) 1 . Introduction O wing to its rapid global spread, the World Health Organization (WHO) declared new coronavirus disease 2019 (COVID-19) as a pandemic on March 11 th , 2020 (1) . The global and national health authorities rapidly implemented measures for social distancing to slow the spread of the virus. These measures include the suspension of all elective hospital visits and procedures (2) . The diversion of resources toward management of COVID-19 as well as the population fear to present to the hospital had an impact on the presentation and management of both acute cardiovascular events like myocardial infarction and stroke and to the chronic heart failure population (2) . Based on the reviews of cases that have been affected by COVID-19, patients with pre-existing cardiovascular disease, especially heart failure, are considered to be at higher risk of developing complications (1, (3) (4) (5) (6) . Also, the healthcare providers are at high risk of getting infected by the virus (7). This document aims to establish a consensus on how to mitigate the risks associated with the pandemic and devise a pathway to manage heart failure patients. Implementation of social distancing and redirecting health care recourses to acute care facilities had led to closing the outpatient visits. The interruption of regular outpatient visits had impacted the heart failure patients negatively by the following: difficulty in accessing their HF specialists, delay in optimizing the guideline-directed therapies and delaying intracardiac defibrillator (ICD) and cardiac resynchronization therapy device (CRTD) implantation (2) . The healthcare institutes had changed rapidly into implementing virtual clinics, which had helped in access to the healthcare provider, health education, and prescribing medication (2, 8) . Nevertheless, the absence of availability of laboratory investigation is limiting further optimization of medical therapy(2). There has been a significant decline in patients presenting to emergency departments for acute symptoms. This is due to the fear of getting in Hospitalized patients remain at risk of getting the infection from asymptomatic carriers among health care workers or visitors. The atypical presentation of heart failure or lack of response to standard therapy should warrant evaluation for COVID-19 infection(9). The currently available evidence shows no significant difference in in-hospital mortality among patients hospitalized with COVID-19 on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) compared to patients who were not on these therapies. Hence, heart failure and hypertension societies recommend the continuation of ACEi and ARBs for all patients who are already on these therapies(11). For HF patients who are currently treated with an ACEi, ARB, or angiotensin receptor Neprilysin inhibitor (ARNI), we recommend continuing treatment as per HF guidelines. Avoid withdrawal of ACEi, ARB, or ARNI in HF patients as this will lead to HF decompensation. In case of acute illness with COVID-19, treatment should continue with currently prescribed medication for HF and HTN unless clinically contraindicated. In case of adverse events such as acute kidney injury or hypotension the ACEi, ARB or ARNI should be stopped until stabilization. In patients with new HF we recommend initiating ACEi or ARBs as per HF management guidelines. Patients listed for heart transplantation or posttransplantation are the most vulnerable population in this current pandemic. The International Heart and Lung Transplant Society (ISHLT) recommends managing heart transplant patients who develop COVID-19 based on the severity of their illness (12) The COVID-19 pandemic has led to unexpected changes in health care delivery. The quality and continuity of care for HF patients are adversely affected. This document explains the current challenges and how to manage it. Further collaboration is needed to understand the long-term effect of the pandemic on the health care system. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic Secondary Impact of the COVID-19 Pandemic on Patients With Heart Failure Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19) and Cardiovascular Disease Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America The Variety of Cardiovascular Presentations of COVID-19 Disposition of emergency department patients diagnosed with acute heart failure: an international emergency medicine perspective Drug Therapy, and Mortality in Covid-19 Guidance from the International Society of Heart and Lung Transplantation Regarding SARS COV-2 Pandemic. ISHLT website